4/A: Brainstorm Cell Therapeutics CEO Amends Filing to Correct Transaction Codes

Chaim Lebovits, CEO of Brainstorm Cell Therapeutics, amends a previous SEC Form 4 filing to correct transaction codes related to common stock purchases.

Summary

• Chaim Lebovits, the President and CEO of Brainstorm Cell Therapeutics, filed an amendment to a previous Form 4 filing with the SEC.
• The amendment corrects transaction codes that were initially reported incorrectly due to an administrative error.
• The corrected filing shows that on May 21, 2024, Lebovits purchased 25,000 shares of common stock at a price of $0.579 per share.
• On May 22, 2024, Lebovits purchased an additional 25,000 shares of common stock at a price of $0.64 per share.
• Following these transactions, Lebovits directly owns 1,149,865 shares of Brainstorm Cell Therapeutics common stock.
• Lebovits may also be deemed the beneficial owner of 2,000,847 indirectly held shares, including 1,933,794 shares owned by ACCBT Corp. and 67,053 shares owned by ACC International Holdings Ltd.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing correcting an administrative error, so it has a neutral sentiment.

Industry Context

This filing is a routine disclosure related to insider trading activity and provides transparency to investors regarding the transactions of company executives.

Stakeholder Impact

• The correction of the filing ensures accurate information is available to shareholders.

Key Dates

Keywords

Form 4, SEC, Chaim Lebovits, Brainstorm Cell Therapeutics, BCLI, Common Stock, Beneficial Ownership, Transaction Codes, Amendment